Proteinase-activated receptor2 agonists upregulate granulocyte colony-stimulating factor, IL-8, and VCAM-1 expression

Rithwik Ramachandran1, Alyn H Morice, Steven J Compton

  • 1Respiratory Medicine, Division of Academic Medicine, Post Graduate Medical Institute of the University of Hull in association with the Hull York Medical School, East Yorkshire, HU16 5JQ, United Kingdom.

Insights

Proteinase-activated receptor 2 (PAR2) plays a role in inflammatory airways disease by influencing bronchial fibroblast responses. PAR2 activation increases VCAM-1 expression and cytokine release, potentially promoting neutrophilic inflammation.

Area of Science:

  • Cellular and Molecular Biology
  • Immunology
  • Respiratory Medicine

Background:

  • Proteinase-activated receptors (PARs) are G-protein-coupled receptors involved in cellular signaling.
  • PAR2 is implicated in inflammatory airways disease, but its role in airway fibroblasts is unclear.
  • Fibroblasts are key players in airway pathology.

Purpose of the Study:

  • To investigate the expression and function of PARs, particularly PAR2, in human primary bronchial fibroblasts (HPBFs).
  • To determine the effects of PAR2 activation on HPBF proliferation, cytokine production (IL-8, G-CSF), and adhesion molecule expression (VCAM-1).

Main Methods:

  • RT-PCR and flow cytometry were used to assess PAR expression in HPBFs.
  • Intracellular calcium signaling assays evaluated PAR functionality.
  • MTT assays measured HPBF proliferation.
  • Cytokine and adhesion molecule expression were analyzed following stimulation with PAR agonists.

Main Results:

  • HPBFs express functional PAR1, PAR2, and PAR3, but not PAR4.
  • PAR2 agonists did not induce HPBF proliferation, while thrombin did.
  • PAR2 activation (SLIGKV-NH2) upregulated IL-8 and G-CSF mRNA, but not protein levels.
  • Trypsin stimulation led to dose- and time-dependent release of IL-8 and G-CSF proteins.
  • Both trypsin and SLIGKV-NH2 increased VCAM-1 expression.

Conclusions:

  • PAR2 activation in bronchial fibroblasts can upregulate VCAM-1 expression and cytokine release.
  • These PAR2-mediated effects may contribute to neutrophilic inflammation in airways.
  • PAR2 represents a potential therapeutic target for inflammatory airway diseases.